Correction: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer

This article has been corrected: In Figure 3B, the caspase 3 blot in the SW-48 column is an accidental duplicate of the caspase 3 blot in the HC-15 column. The corrected Figure 3B, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. Original article: Oncotarget. 2017; 8:68305–68316. https://doi.org/10.18632/oncotarget.20054 Figure 3: Effects of regorafenib in combination with silybin on induction of apoptosis in SW48, SW48-CR, HCT15 and SW480 colon cancer cells. (A) Apoptosis was evaluated with Annexin-V-FITC staining and 7-Amino-Actinomycin D (7-AAD) detection assays using flow cytometry in SW48, SW48-CR, HCT15 and SW480 cancer cells after 24 hours of incubation with silybin (90 μM) or regorafenib (2 μM) and their combination. Histogram of data expressed as percentage of apoptotic cells.*p < 0.05 compared to single treatment. (B) Colon cancer cells were treated with silybin (90 μM) or regorafenib (2 μM) and their combination for 24 hours. Expression of PARP, caspase 3 and 9 were evaluated by immunoblotting as described in Materials and Methods. α-Tubulin was used as the loading control.